Is Privia Health Group, Inc. overvalued or undervalued?

As of 24 October 2025, the valuation grade for Privia Health Group, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 181, which is significantly higher than peers like Globe Life, Inc. at 11.82 and Primerica, Inc. at 12.59. Additionally, the EV to EBITDA ratio is 82.17, compared to Equitable Holdings, Inc. at 9.97, indicating that Privia is trading at a premium relative to its peers.
In terms of performance, Privia Health Group has shown strong returns, with a year-to-date return of 32.94%, outperforming the S&P 500's 15.47% during the same period. However, over three years, it has underperformed the benchmark, with a return of -19.34% compared to the S&P 500's 78.85%. Overall, while Privia Health Group is currently fairly valued, its high valuation ratios suggest caution in the context of its performance relative to peers.